ANRO

Alto Neuroscience is a clinical-stage biopharma with zero product revenue across FY2023-FY2025 and an accumulated deficit of -$201.6M as of Dec 31, 2025. The numbers tell a stark story: net losses widened to -$63.2M in FY2025 (from -$61.4M in FY2024 and -$36.3M in FY2023), operating cash flow worsened to -$51.8M (YoY -9.2%), and ROE is -41.8%. Management explicitly states in the MD&A that 'we expect to continue to generate operating losses and negative operating cash flows for the foreseeable future' and that operating expenses 'will increase substantially' as ALTO-207 advances into Phase 2b/3 alongside five other pipeline assets. This is the textbook profile of a binary-outcome biotech.

The balance sheet looks superficially healthy — $176M cash, $151M equity, liabilities/equity of just 0.22x — but the cash position is only fresh because of the October 2025 Private Placement that raised ~$49.7M net at $5.91/share, well below today's $26.08 price. That financing drove shares outstanding up 18.0% YoY to 31.9M, and the MD&A flags the need for 'substantial additional funding' through 'public or private sales of equity, government or private party grants, debt financings.' At -$51.8M annual burn, current cash funds roughly 3.4 years of operations before another raise — and long-term debt already jumped 57.7% YoY to $16.2M. Dilution is not a tail risk; it is the funding model.